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Abstract
This report regards the case of a 43 year-old HIV-positive woman who developed an episode of
serious transaminase elevation during stavudine-including antiretroviral therapy. Diagnostic
assessment ruled out hepatitis virus co-infection, alcohol abuse besides other possible causes of
liver damage. No signs of lactic acidosis were present. Liver biopsy showed portal inflammatory
infiltrate, spotty necrosis, vacuoles of macro- and micro-vesicular steatosis, acidophil and foamy
hepatocytes degeneration with organelles clumping, poorly formed Mallory bodies and neutrophil
granulocytes attraction (satellitosis). A dramatic improvement in liver function tests occurred when
stavudine was discontinued and a new antiretroviral regimen with different nucleoside reverse
transcriptase inhibitors was used. The importance of considering hepatotoxicity as an adverse
event of HAART including stavudine, even in absence of other signs of mitochondrial toxicity
should therefore be underlined. Liver biopsy may provide further important information regarding
patients with severe transaminase elevation, for a better understanding of the etiology of liver
damage.
Background
Highly active anti-retroviral therapy (HAART) is associ-
ated with a number of serious and potentially life-threat-
ening adverse events, including drug-induced liver injury
(i.e., hepatotoxicity – HT). The potential of nucleoside
reverse transcriptase inhibitors (NRTI) for liver damage
seems to be related to mitochondrial DNA damage and
can also lead to lactic acidosis [1]. Although in vitro data
demonstrated a prominent mitochondrial oxidative stress
in human hepatoma cells exposed to stavudine [2], and a
stronger inhibition of mitochondrial DNA synthesis by
dideoxynucleoside analogues (ddX – i.e., stavudine, dida-
nosine and zalcitabine) than by other NRTI [3], existing
studies have failed to demonstrate any consistent associa-
tion between the use of these drugs and the development
of subsequent HT [4,5]. Their possible causative role is
therefore still under debate.
Case presentation
A 43 year-old woman, HIV positive since 1994 and noti-
fied for AIDS in 2001 due to disseminated cytomegalovi-
rus (CMV) infection, underwent routine laboratory
testing in February 2004, when a significant increase in
alanine amino-transferase (ALT) and aspartate amino-
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transferase (AST) levels was found (222 and 188 IU/L
respectively). Blood re-testing performed after 15 days
showed a further increase in transaminase levels (ALT =
392 IU/L, AST = 446 IU/L). The patient was undergoing
treatment with stavudine (d4T) 40 mg twice daily, tenofo-
vir (TDF) 300 mg once daily and indinavir 800 mg twice
daily, boosted with ritonavir 100 mg twice daily (IDV/r)
with poor viro-immunological response (CD4+ T-cell
count = 140 cells/mm3, HIV-RNA = 1600 copies/ml). The
treatment included d4T and TDF since May 2001 and July
2003 respectively, while IDV/r was initiated in October
2003, replacing lopinavir/ritonavir due to gastro-intesti-
nal side effects. (see Fig. 1).
Appropriate investigations were performed to rule out
possible causes of liver transaminase elevations. The
patient was negative for hepatitis B surface antigen
(HBsAg) with a pattern of isolated positive hepatitis B
core antibodies (HBcAb). However, plasma HBV-DNA
resulted negative. Serum positivity for hepatitis C virus
antibodies (HCV-Ab) was reported in May 2001, but
chronic HCV infection was excluded by HCV-RNA testing,
which resulted undetectable on two consecutive determi-
nations in June and October 2003. Moreover, HCV-RNA
was repeated at the time of HT and still resulted negative.
Further, hepatitis A virus immunoglobulin M (HAV-IgM)
resulted negative and the patient denied any alcohol
abuse or concomitant use of other hepatotoxic drugs.
Suspecting a drug-related liver toxicity, IDV/r, the most
recently introduced antiretroviral agent, was suspended
on February 17th 2004 and replaced by lamivudine (3TC).
Liver function monitoring and diagnostic assessment
were continued.
On March 4th 2004, approximatively one month after ini-
tial transaminase elevation, ALT was 353 IU/L and AST
373 IU/L. HCV-RNA, HBV-DNA, HAV-IgM resulted nega-
tive again, as well as CMV DNA, CMV early-antigen,
Epstein-Barr virus sierology and markers indicating auto-
immune hepatitis. A venous blood gas sample was
obtained, showing pH 7.35, bicarbonate 23 mmol/L, base
excess -1.9 mmol/L and plasma lactate 0.6 mmol/L, ruling
out lactic acidosis. Ethanol was not detectable in patient
serum and no indirect markers of alchol abuse were
present. For instance, gamma-glutamil transferase was
normal or only mildly elavated, erythrocyte mean corpus-
colar volume was within the range of normality during the
entire follow-up and AST/ALT ratio did not support an
acute alcohol hepatitis. Although the patient presented
with lipodistrophy, no signs of metabolic syndrome were
present, since triglyceride, cholesterol, fasting glucose and
uric acid levels were repeatedly measured and always
remained within the range of normality. An abdominal
ultrasonography revealed enlargment of the liver, with
rounded borders and a bright echopattern, while bilary
tract and other intra-abdominal organs were normal.
Although a partial improvement of liver function tests fol-
lowed the therapy switch, three months after IDV/r dis-
continuation, ALT and AST levels were still elevated (182
and 120/IU, respectively). On May 26th  2004, a liver
biopsy was performed (see Fig. 2). Histological analysis
showed deformation of portal tracts profile due to fibro-
sis. Portal tracts contained an inflammatory infiltrate of
low or focally moderate grade with focal interface hepati-
tis. Periportal fibrosis was present. Foci of spotty necrosis,
acidophil bodies, scattered vacuoles of macro- and micro-
vesicular steatosis and scattered lipogranulomas were also
present in lobules. Several hepatocytes, predominantly in
peri-portal areas, showed ballooning degeneration,
clumping of cytoplasm, with the development of poorly-
formed Mallory bodies. Ballooned hepatocytes and the
poorly formed Mallory bodies were surrounded or infil-
trated by neutrophil granulocytes. In addition, scattered
hepatocytes had microvacuolated cytoplasma with foamy
degeneration. Scattered glycogenated nuclei were present.
Immuno-histo-chemical assays excluded the occurrence
of an occult HBV infection, showing no reactivity to
HBsAg and hepatitis B core antigene (HBcAg) in the liver
tissue.
On November 10th 2004, antiretroviral drugs were inter-
rupted because of further transaminase elevation and the
patient underwent further exams, confirming previous
investigations. The patient continued to deny alcohol
abuse.
After the interruption of the antiretroviral drugs, liver
transaminases decreased, so that, on January 20th 2005, a
new treatment with tenofovir (TDF), lamivudine (3TC)
and nelfinavir (NFV) was initiated due to the lowering of
the CD4+ T cells count. Despite the new treatment,
between January 2005 and August 2006, the transaminase
levels decreased significantly and remained just above the
upper limit of normality.
Discussion
This case suggests a relationship between antiretroviral
therapy including d4T and hepatotoxicity. Some authors
have suggested that acute liver enzyme elevation in HIV-
positive patients is often due to previous conditions,
rather than to antiretroviral therapy itself [6]. Specifically,
in patients with chronic viral hepatites coexistence,
HAART-related HT develops more frequently or sooner,
and also in a more severe form [7]. In this group of
patients, liver damage may also be caused by immune
reconstitution and related exacerbation of viral hepatites
[8]. Actual drug-related hepatotoxicities may thus be con-
founded by the natural history of concomitant viral hepa-
tites in these patients.Journal of Medical Case Reports 2007, 1:19 http://www.jmedicalcasereports.com/content/1/1/19
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In vitro studies demonstrated the NRTI are able to inhibit
mithocondrial DNA polymerase, DNA polymerase
gamma in particular [9]. Moreover, some cases of severe
lactate elevation and liver steatosis during HAART includ-
ing d4T have been reported [10]. In the present case, an
important transaminase elevation without lactate eleva-
tion was detected. A liver biopsy documented chronic
aggressive hepatitis of a possible multifactorial etiology,
including initial metabolic disorder with suspected signs
of drug hepatotoxicity. Although the histological findings
were not specific for drug-induced damage, other causes
of liver damage, such as HCV or HBV co-infections, alco-
hol abuse, metabolic syndrome and assumption of con-
comitant hepatotoxic drugs were excluded. Therefore, this
case report may be particularly relevant since pure drug-
induced hepatotoxicity may be postulated, regardless of
the "background" effect of chronic hepatitis co-infections.
The mechanism of d4T toxicity may have been mediated
by liver steatosis, which has already been associated with
d4T and other ddX use [11,12]. A steatotic liver, particu-
larly if some grade of fibrosis is present, may be more sus-
ceptible to the toxic effect of the drugs. Therefore, use of
PI boosted with low dose ritonavir could not be excluded
as causative agent of the first episode of transaminase ele-
vation. Although transaminase levels appeared to par-
tially ameliorate after boosted-PI discontinuation, ALT
levels always remained at least 3 times higher than the
upper limit of normality and a second episode of grade III
hepatotoxicity occurred during a NRTI-based regimen.
Liver transaminases returned to rather normal values only
when NRTIs other than d4T (TDF and 3TC) were admin-
istrated. Some authors have observed that switching to
alternative NRTIs, such as TDF or abacavir, may reduce
lipoatrophy or prevent recurrence of lactic acidosis [13].
Liver transaminase and therapeutic evolution in the study patient Figure 1
Liver transaminase and therapeutic evolution in the study patient. ALT: alanine-amino transferase; AST: aspartate-
amino transferase; 3TC: lamivudine; EFV: efavirenz; d4T: stavudine; LPV/r: lopinavir/ritonavir; TDF: tenofovir; IDV/r: indinavir/
ritonavir; NFV: nelfinavir.Journal of Medical Case Reports 2007, 1:19 http://www.jmedicalcasereports.com/content/1/1/19
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Our patient case suggests that a similar phenomenon may
occur in the event of hepatotoxicity.
Conclusion
This case report underlines the importance of d4T as a
possible causative agent of hepatotoxicity, even in the
absence of other signs of mitochondrial toxicity. Liver
biopsy may provide further important information
regarding patients with severe transaminase elevation, in
order to better assess the possible causative factors.
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Liver biopsy (ematossilin-eosin 40×) showing acidophil bodies and foamy degeneration of hepatocytes suggestive for a toxic- metabolic disorder Figure 2
Liver biopsy (ematossilin-eosin 40×) showing acidophil bodies and foamy degeneration of hepatocytes suggestive for a toxic-
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